


Listing of Claims:

**Claims 1-24 (canceled)**

**Claim 25 (currently amended):** ~~The method of claim 1, wherein the NAALADase inhibitor~~  
is A method for treating retinopathy, age-related macular degeneration or glaucoma comprising  
administering to a mammal in need of such treatment an effective amount of a compound of  
 formula X



or an enantiomer or a pharmaceutically acceptable equivalent of said compound, wherein:

$X^3$  is  $-(CR^{36}R^{37})_nSH$ ,  $-O(CR^{36}R^{37})_2SH$ ,  $-S(CR^{36}R^{37})_2SH$  or  $-NR(CR^{36}R^{37})_2SH$ ;

$n$  is 1-3; and

$R$ ,  $R^{36}$ ,  $R^{37}$ ,  $A^6$ ,  $A^7$ ,  $A^8$  and  $A^9$  are independently hydrogen,  $C_1$ - $C_9$  alkyl,  $C_2$ - $C_9$  alkenyl,  $C_2$ - $C_9$  alkynyl, aryl, heteroaryl, carbocycle, heterocycle, halo, hydroxy, sulfhydryl, nitro, amino, cyano, isocyano, thiocyno, isothiocyno, formamido, thioformamido, sulfo, sulfinio,  $C_1$ - $C_9$  alkylsulfonyl,  $C_1$ - $C_9$  alkoxy,  $C_2$ - $C_9$  alkenoxy, phenoxy or benzyloxy, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle, alkoxy, alkenoxy, phenoxy and benzyloxy are independently unsubstituted or substituted with one or more substituent(s).

**Claim 26 (original)** The method of claim 25, wherein the compound of formula X is selected from the group consisting of:

3-(2-mercaptoethyl)-benzoic acid;  
3-(mercaptomethyl)-benzoic acid;  
2-(mercaptomethyl)-benzoic acid;  
5-hydroxy-2-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-benzoic acid;  
5-[(4-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-5-(phenylmethoxy)-benzoic acid;  
2-(carboxymethoxy)-6-(2-mercaptoethyl)-benzoic acid;  
5-[(3-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-6-(phenylmethoxy)-benzoic acid;  
2-[(2-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
3-(2-mercaptoethyl)-[1,1'-biphenyl]-2,3'-dicarboxylic acid;  
2-(3,3-dimethylbutoxy)-6-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-6-(2-phenylethoxy)-benzoic acid;  
2-[(2-chlorophenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-6-phenoxy-benzoic acid;  
2-(2-mercaptoethyl)-6-phenylamino-benzoic acid;  
2-(2-mercaptoethyl)-6-(phenylthio)-benzoic acid;  
5'-(1,1-dimethylethyl)-3-(2-mercaptoethyl)-[1,1'-biphenyl]-2,3'-dicarboxylic acid;  
3-(2-mercaptoethyl)-[1,1'-biphenyl]-2,4'-dicarboxylic acid;  
2-[(4-carboxy-2-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(4-carboxy-3-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(2-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(3-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(4-chlorophenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-(biphenyl-2-ylmethoxy)-6-(2-mercaptoethyl)-benzoic acid;

2-[(3-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(2-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-6-[(4-methoxyphenyl)methoxy]-benzoic acid;  
2-(2-mercaptoethyl)-6-[(4-methylphenyl)methoxy]-benzoic acid;  
2-[(4-bromo-3-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(2-carboxy-5-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
5-(mercaptomethyl)-2-(2-phenylethoxy)-benzoic acid;  
2-bromo-5-(mercaptomethyl)-benzoic acid;  
4-(mercaptomethyl)-[1,1'-biphenyl]-2,3'-dicarboxylic acid;  
5-(mercaptomethyl)-2-(phenylmethoxy)-benzoic acid; and  
4-bromo-3-(mercaptomethyl)-benzoic acid; and  
enantiomers and pharmaceutically acceptable equivalents.

**Claims 27-49 (canceled)**

**Claim 50 (new):** The method of claim 25, wherein the method is for treating retinopathy.

**Claim 51 (new):** The method of claim 50, wherein the retinopathy is diabetic retinopathy.

**Claim 52 (new):** The method of claim 25, wherein the method is for treating age-related macular degeneration.

**Claim 53 (new):** The method of claim 25, wherein the method is for treating glaucoma.

**Claim 54 (new):** The method of claim 26, wherein the method is for treating retinopathy.

**Claim 55 (new):** The method of claim 54, wherein the retinopathy is diabetic retinopathy.

**Claim 56 (new):** The method of claim 26, wherein the method is for treating age-related macular degeneration.

**Claim 57 (new):** The method of claim 26, wherein the method is for treating glaucoma.

**Claim 58 (new):** A method for treating retinopathy or age-related macular degeneration comprising administering an effective amount of a NAALADase inhibitor to a mammal in need of such treatment.